Next Article in Journal
Nrf2 Expressions Correlate with WHO Grades in Gliomas and Meningiomas
Next Article in Special Issue
Could Vitamin D Analogues Be Used to Target Leukemia Stem Cells?
Previous Article in Journal
A Comparison of Fresh Frozen vs. Formalin-Fixed, Paraffin-Embedded Specimens of Canine Mammary Tumors via Branched-DNA Assay
Previous Article in Special Issue
The Vitamin D Analog, MART-10, Attenuates Triple Negative Breast Cancer Cells Metastatic Potential
Review

The Use of 1α,25-Dihydroxyvitamin D3 as an Anticancer Agent

1
Laboratory of Protein Biochemistry, Faculty of Biotechnology, University of Wroclaw, Joliot-Curie 14a, 50-383 Wroclaw, Poland
2
Institute of Inflammation and Aging, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
3
Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Roman Perez-Fernandez
Int. J. Mol. Sci. 2016, 17(5), 729; https://doi.org/10.3390/ijms17050729
Received: 17 March 2016 / Revised: 22 April 2016 / Accepted: 10 May 2016 / Published: 13 May 2016
The notion that vitamin D can influence the incidence of cancer arose from epidemiological studies. The major source of vitamin D in the organism is skin production upon exposure to ultra violet-B. The very first observation of an inverse correlation between exposure of individuals to the sun and the likelihood of cancer was reported as early as 1941. In 1980, Garland and Garland hypothesised, from findings from epidemiological studies of patients in the US with colon cancer, that vitamin D produced in response to sun exposure is protective against cancer as opposed to sunlight per se. Later studies revealed inverse correlations between sun exposure and the occurrence of prostate and breast cancers. These observations prompted laboratory investigation of whether or not vitamin D had an effect on cancer cells. Vitamin D is not active against cancer cells, but the most active metabolite 1α,25-dihydroxyvitamin D3 (1,25D) has profound biological effects. Here, we review the anticancer action of 1,25D, clinical trials of 1,25D to date and the prospects of the future therapeutic use of new and low calcaemic analogues. View Full-Text
Keywords: cancer; 1α,25-dihydroxyvitamin D; analogues cancer; 1α,25-dihydroxyvitamin D; analogues
MDPI and ACS Style

Marcinkowska, E.; Wallace, G.R.; Brown, G. The Use of 1α,25-Dihydroxyvitamin D3 as an Anticancer Agent. Int. J. Mol. Sci. 2016, 17, 729. https://doi.org/10.3390/ijms17050729

AMA Style

Marcinkowska E, Wallace GR, Brown G. The Use of 1α,25-Dihydroxyvitamin D3 as an Anticancer Agent. International Journal of Molecular Sciences. 2016; 17(5):729. https://doi.org/10.3390/ijms17050729

Chicago/Turabian Style

Marcinkowska, Ewa, Graham R. Wallace, and Geoffrey Brown. 2016. "The Use of 1α,25-Dihydroxyvitamin D3 as an Anticancer Agent" International Journal of Molecular Sciences 17, no. 5: 729. https://doi.org/10.3390/ijms17050729

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop